PatternsRadar
Sign in

VINEETLABVineet Laboratories Limited

NSE
Full chart
36.52INR-1.05 (-2.79%)Close · 6 Oct 2026
26 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹70 CrMarket cap
43.7P/E (TTM)
63.1%Delivery

Filings & corporate actions

20 results filed
CSV
Next results · Q1 FY27
Due — expected by 14 Aug 2026
Estimate: filed 22–45 days after quarter end, last 4 times
Dividend
₹1.00 per share · last 19 Sept 2022
2026
  • 26 AugresultsResults · Q4 FY26 · standalone+0.2%NSE
  • 31 JulshareholdingShareholding · 30 Jun 2026+2.0%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026+8.3%NSE
  • 14 FebresultsResults · Q3 FY26 · standalone-0.2%NSE
  • 2 FebshareholdingShareholding · 2 Feb 2026-1.6%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025-1.7%NSE

Reaction to results · all yearsrose on day 0 in 9 of 20 CSV

QuarterFiledDay 0+5D+20DRel vol
Q4 FY2626 Aug 2026+0.2%-2.9%-9.7%1.1×
Q3 FY2614 Feb 2026-0.2%+4.1%-5.7%0.3×
Q2 FY268 Nov 2025-1.9%-8.5%-12.1%0.8×
Q1 FY2622 Jul 2025+0.6%+2.6%+19.0%0.1×
Q4 FY2513 May 2025+0.2%+13.6%+6.6%0.8×
Q3 FY2512 Feb 2025-0.4%-5.9%-28.0%0.6×
Q2 FY2513 Nov 2024-3.3%-4.5%+11.4%3.2×
Q1 FY2514 Aug 2024-8.3%-3.0%-6.0%1.0×
Q4 FY2430 May 2024-2.1%+8.2%+2.9%0.5×
Q3 FY2413 Feb 2024-5.0%-10.4%-23.9%0.4×
Q2 FY2410 Nov 2023+7.9%+30.8%+29.2%1.6×
Q1 FY2412 Aug 2023-8.9%-10.0%-12.5%1.7×
Q4 FY2329 May 2023+6.3%+8.3%+8.2%6.5×
Q3 FY2315 Feb 20230.0%-4.0%-22.6%0.2×
Q2 FY2315 Nov 2022+0.8%-1.2%-5.1%0.3×
Q4 FY2229 May 2022+9.9%+17.3%+11.7%0.7×
Q3 FY2213 Feb 2022-0.6%-6.5%-18.6%6.3×
Q2 FY2211 Nov 2021+5.0%-10.7%-10.6%2.2×
Q1 FY2213 Aug 2021-4.6%-20.5%-15.0%0.3×
Q4 FY211 Jul 2021+10.0%+61.2%+48.4%—
Average+0.3%+2.9%-1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q4 FY26

CSV
Revenue YoY+34.2%
Profit YoY—
Interest cost YoY+22.8%
Revenue QoQ+20.7%
Profit QoQ+43.2%
CAGR2Y3Y4Y5Y6Y7Y
Revenue-37.2%—-25.3%———
Profit+25.0%—-29.9%———

Key data

CSV
Open38.39
Day range36.32 – 38.39
52-week range27.96 – 49.99
From 52w high-26.9%
RSI (14)50.1
ATR (14)2.05
Volume24.9K
Avg volume (20D)1.16L
Rel volume0.21×
Volatility (1Y)45.9%
Turnover₹9.1L
SMA 50 / 20037.36 / 34.95

Delivery percentage

Latest · 6 Oct 202663.1%
20-day avg66.7%
1-year avg65.8%
Percentile (own history)53rd
Range5.2–100.0%
Sessions1,313

Over the last 20 sessions VINEETLAB settled 66.7% of its traded quantity, which is unusually high for an NSE equity. That is in line with its own one-year average of 65.8%. The latest session ranks higher than 53% of the 1,313 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-2.79%+3.37%-2.61%+9.08%+23.75%+3.16%

Valuation

CSV
Market cap₹70 Cr
P/E (TTM)43.7
EPS (TTM)0.84
Shares outstanding1.92Cr
Listed15 Jun 2021

Ownership

CSV
Promoter5.98%
Promoter Δ QoQ0.00 pp
Public94.02%
FII0.50%
DII0.00%
Pledged0.00%

Quarterly results · standalone

CSV
Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue (₹ Cr)7.417.415.618.9
YoY chg-68.8%-8.1%-13.5%+34.2%
Net profit (₹ Cr)(0.9)0.40.91.2
YoY chg————
Net margin-11.6%2.3%5.4%6.4%
EPS-0.940.430.920.43

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 5.98% · public 94.02%
30 Sept 2021: promoter 35.96%31 Dec 2021: promoter 35.96%31 Mar 2022: promoter 35.96%30 Jun 2022: promoter 35.96%30 Sept 2022: promoter 35.96%31 Dec 2022: promoter 35.96%31 Mar 2023: promoter 38.66%30 Jun 2023: promoter 38.66%30 Sept 2023: promoter 38.66%31 Dec 2023: promoter 37.55%31 Mar 2024: promoter 37.50%30 Jun 2024: promoter 37.50%30 Sept 2024: promoter 36.07%31 Dec 2024: promoter 35.85%31 Mar 2025: promoter 35.85%30 Jun 2025: promoter 29.26%30 Sept 2025: promoter 15.89%31 Dec 2025: promoter 12.46%2 Feb 2026: promoter 5.98%31 Mar 2026: promoter 5.98%30 Jun 2026: promoter 5.98%
2021-092026-06
  • Promoter
  • Public and others
Promoter
5.98%
Public
94.02%
Promoter change
0.00 pp
Filed
31 Jul 2026
FII
0.50%
DII
0.00%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q1 FY24Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26A
Revenue from operations37.543.432.637.023.919.018.114.17.417.415.618.9
Other income0.00.00.00.40.40.20.01.40.00.00.00.0
Total income37.543.432.737.524.219.218.115.57.517.415.718.9
Total expenses38.840.835.036.026.420.923.826.78.417.114.917.9
└ Finance costs1.01.01.11.71.11.01.00.90.62.21.11.0
└ Depreciation0.60.60.60.70.60.60.60.70.60.60.60.5
Profit before tax(1.3)2.5(2.3)1.4(2.2)(1.7)(5.7)(11.2)(0.9)0.40.81.0
Tax expense(0.0)0.1(0.3)(0.5)(0.0)0.10.0(0.7)(0.0)(0.0)(0.0)0.3
Net profit(1.2)2.4(2.1)1.9(2.1)(1.8)(5.7)(10.5)(0.9)0.40.91.2
EPS-1.362.62-2.242.09-2.31-1.98-6.19-11.42-0.940.430.920.43
Net margin-3.33%5.58%-6.33%5.19%-8.93%-9.64%-31.53%-74.77%-11.64%2.30%5.44%6.45%
PBT margin-3.42%5.87%-7.14%3.87%-9.08%-9.03%-31.35%-79.72%-12.12%2.13%5.23%5.26%
Tax rate—4.93%—-34.20%—————-7.91%-4.00%27.09%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 26 Aug 2026.

VINEETLAB at a glance

  • VINEETLAB closed at ₹36.52 on 6 Oct 2026, -2.79% on the day, +3.2% over one year, 26.9% below its 52-week high of ₹49.99.
  • Delivery was 63.1% of traded quantity on 6 Oct 2026, the 53rd percentile of its own 1,313 sessions with a reading (20-session average 66.7%, 1-year average 65.8%).
  • Market capitalisation is ₹70 crore at a trailing P/E of 43.7 (trailing EPS ₹0.84).
  • Q4 FY26 results (standalone, filed 26 Aug 2026): revenue ₹19 crore (+34.2% year on year), net profit ₹1 crore; the price moved +0.2% on the first session after.
  • Promoters held 5.98% at 30 Jun 2026, unchanged on the previous filing.
  • Q1 FY27 results are due; going by past filing dates they were expected by 14 Aug 2026.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE505Y01010
SeriesEQ
Listed15 Jun 2021
History from15 Jun 2021
Sessions1,317

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE